Tag: Anti tuberculosis drugs

In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global emergency, prompting the introduction of a new strategy called DOTS to combat the disease. Understanding **what are the 5 components of DOTS therapy?** is key to grasping this critical public health framework and its pharmacological underpinnings.

As the first new tuberculosis drug approved in over 40 years, bedaquiline (BDQ) has a novel mechanism of action that makes it invaluable for treating multidrug-resistant (MDR) strains. Understanding **what is the MOA of BDQ?** requires delving into its highly specific inhibition of a vital energy-generating enzyme in mycobacteria, leading to bacterial death.

Up to 13.6% of patients on anti-tuberculosis treatment in some studies have developed drug-induced arthralgia, or joint pain. This confirms that, yes, **can anti-TB drugs cause joint pain?**, and this is an important side effect that patients and clinicians must manage throughout the lengthy treatment period.

Pyrazinamide is a critical first-line antibiotic used to treat active tuberculosis (TB). Its inclusion in treatment regimens was a key development that allowed the duration of standard TB therapy to be shortened from nine months to six. So, what is a pyrazinamide tablet used for? It is always used in combination with other drugs to kill *Mycobacterium tuberculosis* bacteria.